In Law360, Zach Blume Discussed Midyear Momentum Driving Biotech IPOs

In a Law360 article, capital markets and mergers & acquisitions partner Zach Blume discussed factors driving the 12 biotechnology initial public offerings (IPOs) announced at midyear.

 Zach notes that despite some headwinds, like conflict in the Middle East and regulatory uncertainty in the biotech sector, he expects the pace of IPOs to continue into the second half of 2026.

"I do think strong companies are still going to succeed in an IPO. There are still a lot of dollars chasing the biotech industry," said Zach.

Zach and capital markets counsel Nick Roper advised Veradermics Inc. in its $256.3 million upsized IPO of more than 15 million shares of its common stock at $17 per share. In February the company was listed on the New York Stock Exchange under the symbol “MANE.” They also advised Veradermics in its May upsized public offering of approximately $384 million and concurrent private placement that raised approximately $414 million.